In this issue:
Adjuvant olaparib for BRCA1/2-mutated breast cancer
PET pathological response for de-escalating chemotherapy in HER2+ early breast cancer
Early breast cancer prognosis for 5 vs. 2 years of adjuvant bisphosphonate
Low-dose tamoxifen for mammographic density reduction
Breast cancer patient correlates of early endocrine therapy discontinuation
Adjuvant endocrine therapy in older, comorbid oestrogen receptor+, node–breast cancer
PROMIS to assess QOL in breast cancer
Extended adjuvant neratinib in copositive early breast cancer
Sapanisertib + exemestane/fulvestrant in hormone receptor+/HER2– advanced/metastatic breast cancer
Eribulin + pembrolizumab for metastatic triple-negative breast cancer
Please login below to download this issue (PDF)